Stany Zjednoczone - angielski - NLM (National Library of Medicine)

virbac ah, inc. - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin 25 mg - clintabs® (clindamycin hydrochloride tablets) (for use in dogs only) are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below: dogs: skin infections (wounds and abscesses) due to coagulase positive staphylococci (staphylococcus aureus or staphylococcus intermedius ). deep wounds and abscesses  due to bacteroides fragilis , prevotella melaninogenicus , fusobacterium necrophorum and clostridium perfringens . dental infections due to staphyloccus aureus , bacteroides fragilis , prevotella melaninogenicus , fusobacterium necrophorum and clostridium perfringens . osteomyelitis due to staphylococcus aureus , bacteroides fragilis , prevotella melaninogenicus , fusobacterium necrophorum and clostridium perfringens . clintabs tablets are contraindicated in animals with a history of hypersensitivity to preparations containing clindamycin or lincomycin. because of potential adverse gastrointestinal effects, do not adminis

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

avkare, inc. - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of colitis, as described in the boxed warning , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometr

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

zoetis inc. - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin 25 mg - antirobe (brand of clindamycin hydrochloride) capsules (for use in dogs only) and aquadrops liquid (for use in dogs and cats) are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below: dogs: skin infections (wounds and abscesses) due to coagulase positive staphylococci (staphylococcus aureus or staphylococcus intermedius) . deep wounds and abscesses due to bacteroides fragilis, prevotella melaninogenicus, fusobacterium necrophorum and clostridium perfringens . dental infections due to staphylococcus aureus, bacteroides fragilis, prevotella melaninogenicus, fusobacterium necrophorum and clostridium perfringens . osteomyelitis due to staphylococcus aureus, bacteroides fragilis, prevotella melaninogenicus, fusobacterium necrophorum and clostridium perfringens . cats: deep wounds and abscesses  due to staphylococcus aureus, staphylococcus intermedius, streptococcus spp. deep wounds and infections due to clostridi

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

zoetis inc. - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin 25 mg in 1 ml - antirobe (brand of clindamycin hydrochloride) capsules (for use in dogs only) and aquadrops oral solution (for use in dogs and cats) are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below: dogs: skin infections (wounds and abscesses) due to coagulase positive staphylococci (staphylococcus aureus or staphylococcus intermedius ). deep wounds and abscesses due to bacteroides fragilis, prevotella melaninogenicus, fusobacterium necrophorum and clostridium perfringens . dental infections due to staphylococcus aureus, bacteroides fragilis, prevotella melaninogenicus, fusobacterium necrophorum and clostridium perfringens . osteomyelitis due to staphylococcus aureus, bacteroides fragilis, prevotella melaninogenicus, fusobacterium necrophorum and clostridium perfringens . cats: skin infections (wounds and abscesses) due to staphylococcus aureus, staphylococcus intermedius, streptococcus spp. deep wounds

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

butler animal health supply, llc dba covetrus north america - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin hydrochloride oral drops (for use in dogs and cats) is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below: skin infections (wounds and abscesses) due to coagulase positive staphylococci (staphylococcus aureus or staphylococcus intermedius ). deep wounds and abscesses due to bacteroides fragilis , prevotella melaninogenicus , fusobacterium necrophorum and clostridium perfringens . dental infections due to staphylococcus aureus , bacteroides fragilis , prevotella melaninogenicus , fusobacterium necrophorum and clostridium perfringens . osteomyelitis due to staphylococcus aureus , bacteroides fragilis , prevotella melaninogenicus , fusobacterium necrophorum and clostridium perfringens . skin infections (wounds and abscesses) due to staphylococcus aureus , staphylococcus intermedius and streptococcus spp. deep wounds and infections due to clostridium perfringens and bacteroides fragilis . dental infections due to staphylococcus aureus , staphylococcus intermedius , streptococcus spp., clostridium perfringens and bacteroides fragilis. clindamycin hydrochloride oral drops is contraindicated in animals with a history of hypersensitivity to preparations containing clindamycin or lincomycin. because of potential adverse gastrointestinal effects, do not administer to rabbits, hamsters, guinea pigs, horses, chinchillas or ruminating animals.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

remedyrepack inc. - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin hydrochloride capsules, usp are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin hydrochloride capsules, usp are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of colitis, as described in the boxed warning , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. streptococci: serious respiratory tract infections; serious skin and soft tissue infections. staphylococci: serious respiratory tract infections; serious skin and soft tissue infections. pneumococci: serious respiratory tract infections. bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules, usp and other antibacterial drugs, clindamycin hydrochloride capsules, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. clindamycin hydrochloride capsules are contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

remedyrepack inc. - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin hydrochloride capsules, usp are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin hydrochloride capsules, usp are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of colitis, as described in the boxed warning , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. streptococci: serious respiratory tract infections; serious skin and soft tissue infections. staphylococci: serious respiratory tract infections; serious skin and soft tissue infections. pneumococci: serious respiratory tract infections. bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules, usp and other antibacterial drugs, clindamycin hydrochloride capsules, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. clindamycin hydrochloride capsules are contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

remedyrepack inc. - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of colitis, as described in the   boxed warning , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. streptococci: serious respiratory tract infections; serious skin and soft tissue infections. staphylococci: serious respiratory tract infections; serious skin and soft tissue infections. pneumococci: serious respiratory tract infections. bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules usp and other antibacterial drugs, clindamycin hydrochloride capsules usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. clindamycin hydrochloride is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

remedyrepack inc. - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin hydrochloride capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin hydrochloride capsules are also indicated in the treatment of seri­ous infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of colitis, as described in the boxed warning , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastroin­testinal tract); infections of the female pelvis and geni­tal tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. streptococci: serious respiratory tract infections; seri­ous skin and soft tissue infections. staphylococci: serious respiratory tract infections; serious skin and soft tissue infections. pneumococci: serious respiratory tract infections. bacteriologic studies should be performed to deter­mine the causative organisms and their susceptibility to clindamycin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride and other antibacterial drugs, clindamycin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacte­ria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. clindamycin hydrochloride capsules are contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

direct rx - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of colitis, as described in the boxed warning, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometri